HI
STLNW

HBK Investments’s Starling Oncology Warrant STLNW Stock Holding History

HBK Investments’s Portfolio STLNW Stock Details STLNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-14,000
Closed -$10K – 820
2021
Q4 		$10K Buy
+14,000
New +$17.3K ﹤0.01% 699

Other funds holding STLNW

LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
DCM
Difesa Capital Management New York $38.1M AUM 39.86% 1-Year Est. Return
USPCM
Union Square Park Capital Management New York $278M AUM 50.01% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $62.7B AUM 29.77% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

HBK Investments's STLNW Position: Q1 2022 in Review

HBK Investments sold out of Starling Oncology Warrant (STLNW) in Q1 2022, closing a stake of 14,000 shares — an estimated $10K sold.

HBK Investments first reported a position in STLNW in Q4 2021 and held it in 1 quarter. The position peaked at $10K in Q4 2021. 12 funds tracked by Wall St. Rank hold STLNW as of Q1 2022.

  • HBK Investments reported no remaining Starling Oncology Warrant position as of Q1 2022 after selling out during the quarter.
  • HBK Investments sold 14,000 Starling Oncology Warrant shares in Q1 2022, an estimated $10K.
  • HBK Investments first reported a position in Starling Oncology Warrant in Q4 2021 and held it in 1 quarter.
  • HBK Investments's Starling Oncology Warrant position peaked at $10K in Q4 2021.
  • 12 funds tracked by Wall St. Rank held Starling Oncology Warrant as of Q1 2022.

Based on HBK Investments's 13F filing for Q1 2022, filed 16 May 2022.